Please login to the form below

Not currently logged in
Email:
Password:

Pfizer considers Icagen options

Pfizer is considering a "strategic transaction" with Icagen, a US biotechnology company, in which it holds a 14 per cent stake in

Pfizer is considering a "strategic transaction" with Icagen, a US biotechnology company, in which it holds a 14 per cent stake in.

In a regulatory filing, Pfizer said Icagen representatives and Pfizer employees have engaged in preliminary discussions, and that Icagen had provided access to due diligence materials.

Pfizer said the continuing talks could lead to an extension or amendment of their longstanding agreement, including a change in its control "by means of a stock or asset acquisition or merger."

Icagen acknowledged that it is engaged in preliminary discussions with Pfizer, however, said there can be no assurance any agreement will be reached.

In 2007 Pfizer forged a research and licensing deal with Icagen, relating to medicines to treat pain and related disorders.

27th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...

Infographics